Fragmin

Package leaflet: information for the patient

FRAGMIN 2,500 IU anti-Xa/0.2 ml, solution for injection
FRAGMIN 5,000 IU anti-Xa/0.2 ml, solution for injection
FRAGMIN 7,500 IU anti-Xa/0.3 ml, solution for injection
FRAGMIN 10,000 IU anti-Xa/0.4 ml, solution for injection
FRAGMIN 2,500 IU anti-Xa/ml, solution for injection
Dalteparinum natricum

Please read all of this leaflet carefully before using this medicine, as it contains important information for you.

• Keep this leaflet. You may need to read it again.
• If you have any further questions, ask your doctor or pharmacist.
• This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.
• If you experience any side effects, including any not listed in this leaflet, tell your doctor or pharmacist. See section 4.

Contents of the leaflet

1. What Fragmin is and what it is used for
2. Important information before using Fragmin
3. How to use Fragmin
4. Possible side effects
5. How to store Fragmin
6. Contents of the pack and other information

1. What Fragmin is and what it is used for

Fragmin is an anticoagulant medicine containing dalteparin sodium. Dalteparin sodium is a low-molecular-weight heparin. The anticoagulant effect of dalteparin is related to its ability to enhance inhibition of factor Xa and thrombin.

Fragmin is indicated for use in adult patients aged over 18 years for:

• Treatment of acute deep vein thrombosis.
• Unstable coronary artery disease (e.g. resting angina, myocardial infarction without Q wave).
• Long-term treatment of symptomatic venous thromboembolic disease (proximal deep vein thrombosis and pulmonary embolism) to reduce recurrence of thromboembolic events in patients with cancer.
• Prevention of blood clotting in extracorporeal circulation, e.g. during hemodialysis and hemofiltration in acute or chronic renal failure.
• Prophylaxis of thromboembolic complications associated with surgical procedures.
• Thromboprophylaxis in medically immobilized patients: with congestive heart failure in NYHA class III or IV or acute respiratory failure, acute infection, acute rheumatic disease or acute inflammatory bowel disease, and at least one additional risk factor for deep vein thrombosis, e.g. age over 75 years, obesity, cancer, history of deep vein thrombosis.

Fragmin is indicated for use in children and adolescents for:

• Treatment of blood clots in veins (venous thromboembolic disease (VTE)) in children and adolescents aged 1 month and older.

2. Important information before using Fragmin

When not to use Fragmin

• if the patient is allergic to dalteparin sodium or another low-molecular-weight heparin, or unfractionated heparin, or to any of the other ingredients of this medicine (listed in section 6);
• confirmed or suspected immune-mediated heparin-induced thrombocytopenia;
• active bleeding, e.g. from the gastrointestinal tract or cerebral vessels;
• severe coagulation disorders;
• acute or subacute bacterial endocarditis;
• recent trauma or surgical procedures involving the central nervous system, eyes and (or) ears. Due to increased risk of bleeding, high doses of dalteparin sodium (used, for example, in the treatment of acute deep vein thrombosis, pulmonary embolism, and unstable coronary artery disease) must not be administered to patients undergoing spinal or epidural anaesthesia or other procedures requiring lumbar puncture.

Warnings and precautions
Before starting treatment with Fragmin, discuss the following with your doctor or pharmacist.

• In patients prior to spinal anaesthesia (epidural or intrathecal) or lumbar puncture. Patients receiving anticoagulant medicines such as low-molecular-weight heparins or heparinoids for prevention of thromboembolic complications are at risk of developing epidural or subdural haematoma, which may result in long-term or permanent paralysis. The risk of such complications is increased when a permanent catheter is inserted into the epidural space for anaesthetic administration, and when other medicines affecting haemostasis (such as non-steroidal anti-inflammatory drugs, platelet inhibitors, and other anticoagulants) are used concomitantly. Traumatic or repeated epidural or lumbar punctures also appear to increase this risk. Such patients should be closely monitored, with frequent assessment of both subjective and objective neurological signs.
• In patients with: thrombocytopenia, platelet function disorders, severe hepatic or renal impairment, untreated or uncontrolled hypertension, or hypertensive or diabetic retinopathy. High doses of dalteparin sodium, such as those required for treatment of deep vein thrombosis, pulmonary embolism, or unstable coronary artery disease, should be used cautiously in patients who have recently undergone surgery or have other conditions increasing the risk of bleeding.
• For thromboprophylaxis, insertion or removal of an epidural or intrathecal catheter should be performed at least 10–12 hours after the last dose of dalteparin. In patients receiving higher doses of Fragmin (e.g. 100–120 IU/kg body weight every 12 hours or 200 IU/kg body weight once daily), the interval should be at least 24 hours.
• In patients who have received epidural or intrathecal anaesthesia, neurological monitoring for signs of neurological impairment (such as back pain, sensory disturbances or weakness in the lower limbs, or bladder or bowel dysfunction) should be ensured. If any of these symptoms occur, the nurse or doctor should be informed immediately.
• In patients suspected of having epidural or subdural haematoma, treatment may require surgical decompression of the spinal cord.
• In patients with heart valve prostheses. Prophylactic doses of Fragmin are not sufficient to prevent thrombosis on the valves in these patients.
• In patients with pulmonary embolism who also have circulatory disorders, low blood pressure, or are in shock, due to lack of clinical experience with Fragmin in such cases.
• In patients who develop rapidly progressing or severe thrombocytopenia (platelet count less than 100,000/µL or mm³) during treatment. The doctor should order platelet count measurement before starting Fragmin and monitor it regularly during treatment. In vitro testing for platelet antibodies in the presence of unfractionated heparin or low-molecular-weight heparins is recommended. If the test result is positive or inconclusive, or if such testing has not been performed, the doctor should discontinue Fragmin treatment.
• In children and adolescents, patients with renal impairment, patients with severe underweight or obesity, pregnant women, or patients at increased risk of bleeding or recurrent thrombosis, the doctor may consider monitoring the anticoagulant effect of dalteparin sodium. The doctor will recommend appropriate tests.
• In patients undergoing long-term dialysis, the doctor will recommend appropriate dose adjustment based on anti-Xa activity testing. In patients undergoing emergency haemodialysis, frequent monitoring of anti-Xa activity is required.
• In patients with unstable coronary artery disease, such as unstable angina or non-Q-wave myocardial infarction, who have experienced full-thickness myocardial infarction. In such patients, the doctor may recommend thrombolytic therapy (to restore blood flow in occluded or narrowed blood vessels). Concomitant use of Fragmin and thrombolytic agents increases the risk of bleeding; however, this does not mean that Fragmin should be discontinued.
• In patients with unstable coronary artery disease treated long-term with Fragmin and with impaired renal function (creatinine concentration >150 µmol/L). In such patients, the doctor may consider reducing the dose.
• In patients with latex allergy (natural rubber) or suspected latex allergy, or in individuals who may come into contact with the needle cap of the Fragmin pre-filled syringe. The needle cap of the Fragmin pre-filled syringe may contain latex (natural rubber). In individuals with latex hypersensitivity, severe allergic reactions may occur.
• Due to the risk of haematoma formation, intramuscular injections should be avoided in patients treated with Fragmin at daily doses exceeding 5,000 IU.
• In patients (particularly those with chronic renal failure and diabetes), heparin may reduce aldosterone secretion, leading to increased blood potassium levels (hyperkalaemia). The risk of hyperkalaemia appears to increase with duration of treatment but is usually reversible. The doctor should order potassium level testing before starting treatment and monitor it regularly during treatment, especially in high-risk patients and when treatment lasts longer than 7 days.

Interchangeability with other anticoagulants
Dalteparin must not be used interchangeably (unit for unit) with unfractionated heparin, other low-molecular-weight heparins, or synthetic polysaccharides. Each of these medicines differs in terms of raw materials, manufacturing process, and physicochemical, biological, and clinical properties, leading to differences in dosing and possibly clinical efficacy and safety. Each medicine is unique and requires adherence to specific medical instructions for use.

Children
Fragmin must not be used in neonates under 1 month of age.

Fragmin and other medicines
Inform your doctor or pharmacist about all medicines currently used or recently used, as well as any medicines planned for future use.
Some medicines may affect the action of Fragmin, and Fragmin may reduce the effectiveness of other medicines taken simultaneously.
Thrombolytic therapy (clot-dissolving) or certain medicines affecting blood coagulation may increase the risk of bleeding when used concomitantly with Fragmin:

• aspirin (acetylsalicylic acid);
• platelet aggregation inhibitors (used to reduce platelet aggregation and risk of blood clot formation);
• thrombolytic agents (used to dissolve blood clots);
• non-steroidal anti-inflammatory drugs (NSAIDs) (used to treat inflammatory conditions);
• GP IIb/IIIa receptor antagonists (affecting platelet aggregation, used in treatment of heart disease);
• vitamin K antagonists and other types of anticoagulants;
• dextran (used in certain artificial tears).

Medicines that increase the effect of Fragmin:

• medicines used to thin the blood (dipyridamole);
• certain medicines used to treat gout (e.g. sulfinpyrazone, probenecid);
• certain diuretics (e.g. ethacrynic acid);
• solutions administered to increase blood volume;
• cytostatic medicines (used in cancer treatment).

Medicines that may reduce the effect of Fragmin:

• medicines used to treat allergies and hay fever (e.g. antihistamines);
• medicines used to treat heart failure and circulatory disorders (e.g. cardiac glycosides such as digoxin, digitoxin);
• tetracycline antibiotics used to treat bacterial infections;
• vitamin C (e.g. contained in vitamin preparations);
• andexanet alfa (used to reverse the effects of certain anticoagulants such as apixaban or rivaroxaban).

Other medicines that may affect the action of Fragmin:

• medicines used to treat angina pectoris (e.g. intravenous nitroglycerin);
• antibiotics such as high-dose penicillins used to treat bacterial infections;
• medicines used for prevention and treatment of malaria (e.g. quinine);
• nicotine from smoking or smoking cessation products.

Particular caution is required in patients with renal impairment when Fragmin is used concomitantly with NSAIDs and high-dose acetylsalicylic acid (aspirin). In patients with unstable coronary artery disease, aspirin should be used only at low doses.

Pregnancy, breastfeeding and fertility

If the patient is pregnant or breastfeeding, suspects she may be pregnant, or plans to become pregnant, she should consult her doctor or pharmacist before using this medicine.

Pregnancy
This medicine should be used during pregnancy only if clearly necessary.

Breastfeeding
Small amounts of dalteparin sodium pass into human milk. A risk to breastfed infants cannot be excluded. Fragmin may be used during breastfeeding, taking into account the benefits of breastfeeding for the infant and the benefits of therapy for the mother.

Fertility
No data are available indicating an effect of Fragmin on fertility.

Driving and using machines
Fragmin has no influence on the ability to drive or operate machinery.

Fragmin contains sodium

Fragmin 2,500 IU anti-Xa/0.2 mL, Fragmin 5,000 IU anti-Xa/0.2 mL, Fragmin 7,500 IU anti-Xa/0.3 mL, and Fragmin 10,000 IU anti-Xa/0.4 mL contain less than 1 mmol (23 mg) of sodium per pre-filled syringe, meaning these medicines are considered "sodium-free".

Fragmin 2,500 IU anti-Xa/mL (4 mL vial) contains 24.2 mg of sodium (main component of table salt) per vial, equivalent to 1.21% of the recommended maximum daily dietary sodium intake for adults.

This medicine may be diluted with solutions containing sodium. Inform your doctor if the patient or child is on a low-sodium diet.

3. How to use Fragmin

This medicine should always be used as directed by the physician or pharmacist. If in doubt,
consult the physician or pharmacist.
Fragmin is administered subcutaneously, intravenously, or extracorporeally (in the dialysis circuit).
Fragmin must not be administered intramuscularly.
For the treatment of blood clots in the patient's circulation, Fragmin is given subcutaneously.
If the patient is undergoing hemodialysis or hemofiltration (procedures used to clean the blood),
Fragmin is administered intravenously or into the dialysis tubing.
Dalteparin may be mixed with isotonic infusion solutions of sodium chloride (9 mg/ml) or glucose
(50 mg/ml) in glass bottles or plastic containers.
Dosage and method of administration
If the dose required for the patient cannot be achieved with Fragmin, alternative medications should be used.
Treatment of acute deep vein thrombosis
Fragmin may be administered subcutaneously once or twice daily.
During treatment with Fragmin, concomitant administration of vitamin K antagonists may be initiated.
Fragmin should be continued until the levels of the prothrombin complex factors (factors: II,
VII, IX, X) have decreased to therapeutic levels. This usually occurs after approximately 5 days
of combined treatment. Outpatient treatment is possible using the same doses as those used in hospital.
Once-daily administration
Dose: 200 IU/kg body weight subcutaneously once daily. Monitoring of anticoagulant effect is not required.
A single daily dose exceeding 18,000 IU should not be used.
Dosing from the single-use pre-filled syringe can be determined according to the table below.

Administration twice daily
Alternatively, a dose of 100 IU/kg body weight may be administered subcutaneously twice daily. Routine monitoring of anticoagulant effect is generally not required; however, it should be considered in selected patients (see section 2: Warnings and precautions). Blood samples should be taken at the time of peak plasma concentration (3 to 4 hours after subcutaneous injection). The recommended peak plasma concentrations range from 0.5 to 1.0 IU anti-Xa/mL.

Prevention of blood clotting in extracorporeal circulation, e.g. during hemodialysis and hemofiltration in acute or chronic renal failure
Fragmin should be administered into the arterial line of the dialysis device or intravenously, selecting the most appropriate of the dosing regimens described below.

• Patients with chronic renal failure and without documented increased bleeding risk
  These patients usually require only minor dose adjustments; therefore, frequent monitoring of anti-Xa activity is generally not necessary in most of them.

• Hemodialysis and hemofiltration lasting no longer than 4 hours
  At the beginning of the procedure, a single intravenous bolus injection may be given either intravenously or into the extracorporeal arterial line. The recommended initial dose is 5,000 IU; alternatively, a lower initial dose may be used when clinically indicated. The initial dose of 5,000 IU for the single bolus regimen may be adjusted from session to session based on the results of the previous dialysis; the dose may be gradually increased or decreased by 500 or 1,000 IU until a satisfactory effect is achieved. Alternatively, an intravenous bolus injection of 30 to 40 IU/kg total body weight may be given, followed by a continuous intravenous infusion of 10 to 15 IU/kg body weight per hour.

• Hemodialysis and hemofiltration lasting longer than 4 hours
  A single intravenous bolus injection of 30 to 40 IU/kg body weight, followed by a continuous intravenous infusion of 10 to 15 IU/kg body weight per hour.

• Patients with acute renal failure or increased risk of bleeding
  Intravenous bolus injection of 5 to 10 IU/kg body weight, followed by continuous intravenous infusion of 4 to 5 IU/kg body weight per hour. These patients may be more unstable and may require monitoring of anti-Xa levels. Plasma anti-Xa concentration should be maintained within the range of 0.2–0.4 IU/mL.

Prophylaxis of thromboembolic complications associated with surgical procedures
Fragmin should be administered subcutaneously. Routine monitoring of anticoagulant effect is generally not required. If monitoring is performed, blood samples should be taken at the time of peak plasma concentration (3 to 4 hours after subcutaneous injection). The recommended doses generally result in peak plasma activity ranging from 0.1 to 0.4 IU anti-Xa/mL.

General surgical procedures
Select the appropriate dosing regimen from those listed below.

• Patients at risk of thromboembolic complications
  2,500 IU subcutaneously 2 hours before surgery and 2,500 IU subcutaneously each morning after surgery until patient mobilization (usually treatment lasts 5 to 7 days or longer).

• Patients with additional risk factors for thromboembolic complications (e.g. cancer)
  Administer Fragmin until patient mobilization (usually for 5 to 7 days or longer).

  1. Start treatment the day before surgery: 5,000 IU subcutaneously in the evening before surgery. After surgery, administer 5,000 IU subcutaneously each evening.
  2. Start treatment on the day of surgery: 2,500 IU subcutaneously within 2 hours before surgery and 2,500 IU subcutaneously 8 to 12 hours later, but not earlier than 4 hours after completion of surgery. From the next day after surgery, administer 5,000 IU subcutaneously each morning.

Orthopedic surgery (e.g. hip replacement surgery)
Administer Fragmin for up to 5 weeks after surgery, selecting one of the treatment regimens below:

1. Start treatment before surgery – evening before surgery: 5,000 IU subcutaneously in the evening before surgery. After surgery, 5,000 IU subcutaneously each evening.
2. Start treatment before surgery – day of surgery: 2,500 IU subcutaneously within 2 hours before surgery and 2,500 IU subcutaneously 8 to 12 hours later, but not earlier than 4 hours after completion of surgery. From the day after surgery, administer 5,000 IU subcutaneously daily.
3. Start treatment after surgery: 2,500 IU subcutaneously 4 to 8 hours after surgery, but not earlier than 4 hours after completion of surgery. From the day after surgery, administer 5,000 IU subcutaneously daily.

Prophylaxis of acute deep vein thrombosis in medically immobilized patients
The recommended dose of Fragmin is 5,000 IU once daily. Treatment with dalteparin sodium should continue until the end of the immobilization period, for up to 14 days or longer. Routine monitoring of anticoagulant effect is generally not required.

Duration of administration
Antithrombotic prophylaxis in patients with significantly increased thromboembolic risk who are temporarily immobilized due to severe illness such as heart failure, respiratory failure, or severe infection should continue until full mobilization of the patient. The duration of treatment depends on the patient's condition and is usually 14 days.

Method of administration
The drop at the tip of the needle should be removed before injection, as the presence of dalteparin sodium in the injection needle may lead to a harmless superficial hematoma or, rarely, local irritation.
For detailed injection instructions, see section below: How to inject Fragmin.

Unstable angina and non-Q-wave myocardial infarction
Routine monitoring of anticoagulant effect is generally not required; however, it should be considered in selected patients (see section 2: Warnings and precautions). Blood samples should be taken at the time of peak plasma concentration (3 to 4 hours after subcutaneous injection). The recommended peak plasma anti-Xa activity ranges from 0.5 to 1.0 IU/mL. Concomitant administration of acetylsalicylic acid (at a dose of 75 to 325 mg daily) is recommended. Administer Fragmin at a dose of 120 IU/kg body weight subcutaneously every 12 hours, up to a maximum dose of 10,000 IU every 12 hours. Continue treatment until clinical stabilization of the patient (usually for at least 6 days) or longer if deemed beneficial by the physician. Thereafter, prolonged treatment with a fixed dose of Fragmin is recommended until revascularization procedures (such as percutaneous interventions or coronary artery bypass grafting) are performed. The drug should not be used for longer than 45 days. The dose of Fragmin is determined based on the patient's sex and body weight:

• For women with body weight less than 80 kg and men with body weight less than 70 kg: administer 5,000 IU subcutaneously every 12 hours.
• For women with body weight at least 80 kg and men with body weight at least 70 kg: administer 7,500 IU subcutaneously every 12 hours.

Long-term treatment of symptomatic venous thromboembolic disease (proximal deep vein thrombosis and pulmonary embolism) to reduce recurrence of thromboembolic events in cancer patients

Month 1
During the first 30 days of treatment, Fragmin should be administered once daily subcutaneously (s.c.) at a dose of 200 IU/kg body weight. The total daily dose should not exceed 18,000 IU.

Months 2–6
Fragmin should be administered once daily subcutaneously at a dose of approximately 150 IU/kg body weight. The dose to be administered from a single-dose pre-filled syringe is determined according to the table below.

Dose reduction in the case of thrombocytopenia during chemotherapy
The following dosing guidelines were used in clinical trials:
In cases of chemotherapy-induced thrombocytopenia with platelet counts <50,000/mm³, administration of Fragmin should be withheld until the platelet count returns to above 50,000/mm³. If the platelet count is between 50,000 and 100,000/mm³, the dose of Fragmin should be reduced by 17% to 33% of the initial dose (depending on the patient's body weight). Once the platelet count returns to ≥100,000/mm³, the full dose of Fragmin should be resumed.
Table 1. Dose reduction of Fragmin in case of thrombocytopenia in the range of 50,000 – 100,000/mm³, dosing using single-dose pre-filled syringes

Renal impairment
In cases of significant renal impairment defined as creatinine concentration exceeding
3 times the upper limit of normal, the dose of Fragmin should be adjusted to maintain
anti-Xa levels within the therapeutic range of 1 IU/ml (range 0.5–1.5 IU/ml), measured 4–6 hours after
injection. If anti-Xa levels are below or above the therapeutic range, the dose of Fragmin should be
appropriately increased or decreased. Anti-Xa level determination should be repeated after
administration of 3–4 injections at the newly adjusted dose. This dose adjustment regimen should
be repeated until anti-Xa levels reach the therapeutic range.

Use in children and adolescents
Treatment of blood clots in veins (venous thromboembolic disease (VTE))
Recommended doses depend on body weight and the child's age group and will be calculated by the
physician. The physician will inform you of the individualized dose of Fragmin according to these
criteria. Do not change the dosing regimen or treatment schedule without consulting your physician.
The recommended initial dose for children and adolescents according to age is as follows:
Infants from 1 month to below 2 years of age: 150 IU/kg body weight twice daily.
Children from 2 years to below 8 years of age: 125 IU/kg body weight twice daily.
Children from 8 years and adolescents up to 18 years of age: 100 IU/kg body weight twice daily.
The effect of Fragmin is monitored after administration of the initial dose, and the dose will then be
adjusted based on blood testing.

How to inject Fragmin
Fragmin is administered subcutaneously. This section of the leaflet explains how to administer Fragmin
to yourself or your child. Follow these instructions only after proper training by a healthcare
professional. If you are uncertain about any step, contact your physician immediately. Administer
the Fragmin dose at the times of day recommended by your physician.
If dilution of Fragmin is required before administration to children, it should be performed by
qualified medical personnel. Follow your physician's instructions regarding the method and timing
of administration of the diluted solution.

Perform the following steps

Step 1: Preparing the pre-filled syringe for injection of Fragmin
Remove the cap from the pre-filled syringe. An air bubble will appear in the pre-filled syringe.
This air bubble should remain near the plunger and should not be expelled before injection. The
pre-filled syringe is ready for injection. Proceed to Step 2.

The Needle-Trap needle safety device has been specifically designed to prevent needlestick injuries
after proper administration of Fragmin. It consists of a plastic safety device attached to the label
affixed to the syringe. It serves to prevent accidental needlesticks after proper injection of Fragmin.
The Needle-Trap safety device consists of a plastic clip (catcher) positioned parallel along the needle,
securely attached to the label on the syringe barrel.
To activate the safety system, perform the following: Lift the syringe, grasp the end of the plastic
needle clip, and bend it away from the sheath (see Fig. 1).
Fig. 1

Remove the grey rubber needle sheath by pulling it straight off (see Fig. 2).
Fig. 2

An air bubble may be visible in the pre-filled syringe. This is normal and should be ignored.
Do not press the plunger yet, as some of the medication may be lost. Air bubbles in single-use
pre-filled syringes should not be expelled before injection, as this may lead to loss of medication
and thus reduce the administered dose. The pre-filled syringe is ready for injection. Proceed to
Step 2.

Step 2: Selecting and preparing the subcutaneous injection site
Select one of the recommended injection sites shown below (see shaded areas in Fig. 3):
The "U"-shaped area around the navel.
The middle side of the thigh.
Fig. 3

• Each time a dose is administered, inject at a different site.
• Do not inject into areas where the skin is tender, bruised, red, or hard. Avoid areas with scars.
• If the adult or child has psoriasis, do not inject directly into any raised, thick, red, or scaly skin patches ("psoriatic skin lesions").
• Wash and dry your hands.
• Clean the injection site with a new alcohol swab using circular motions. Allow the skin to dry completely. Do not touch the area again before injection.

Step 3: Assuming the correct position
The adult or child should be sitting or lying down for deep subcutaneous injection. If the patient is
administering the injection to themselves, they should sit in a comfortable seated position allowing
clear visibility of the abdomen (see Fig. 4).
Fig. 4

Step 4:
Using the thumb and index finger of one hand, pinch a skin fold. Hold the syringe in the other hand
like a pencil. This will be the injection site.

Step 5:
When injecting Fragmin to an adult or to yourself, hold the pre-filled syringe over the skin fold at a
right angle (i.e., vertically, as shown in the diagram, not at an angle). Insert the needle into the skin
until it is fully inserted (see Fig. 5).
Fig. 5

When injecting Fragmin to a child, insert the needle into the skin with a quick, short motion at an
angle between 45° and 90° (see Fig. 6).
Fig. 6

Step 6:
Press the plunger slowly and steadily to the end to administer the correct dose. Continue holding
the skin fold during injection, then release it and withdraw the needle.
If bleeding occurs at the injection site, apply gentle pressure. Do not rub the injection site, as this
may cause bruising.
Apply a swab to the injection site for 10 seconds. Minor bleeding may occur. Do not rub the
injection site. The injection site may be covered with a dressing.

Step 6: If the syringe has a Needle-Trap needle safety device, activate the needle safety
Place the plastic clip onto a hard, stable surface and, with one hand, rotate the syringe barrel upward
toward the needle, pushing the needle into the sheath where it will lock in place (see Fig. 7).
Continue bending the needle until the syringe exceeds a 45-degree angle with the flat surface,
rendering it permanently unusable (see Fig. 8).
Fig. 7 Fig. 8

Step 7:
Dispose of the pre-filled syringe and needle into a sharps container. Keep the sharps container in a
place inaccessible to others. When the sharps container is nearly full, dispose of it according to
instructions or contact your physician or nurse.

The dose will be adjusted according to the child's age and body weight. Younger children may
require a slightly higher dose of Fragmin per kg body weight than adults. The physician will adjust
the appropriate dose for the patient. To monitor the effect of Fragmin, medical personnel may take
a blood sample during treatment.

Use of Fragmin in patients with renal or hepatic impairment
Fragmin requires cautious use in patients with renal or hepatic impairment (see section 2: Warnings and precautions).

Administration of a higher than recommended dose of Fragmin
Depending on the symptoms present, the physician will administer appropriate treatment. The
anticoagulant effect of Fragmin can be neutralized by administration of protamine. However,
protamine inhibits primary hemostasis; therefore, it should only be used in cases of actual risk.
A dose of 1 mg protamine partially neutralizes the effect of 100 IU (anti-Xa) of Fragmin (although
the prolonged clotting time is fully neutralized, 25%–50% of dalteparin sodium anti-Xa activity
persists).

4. Possible adverse reactions

Like all medicines, this medicine can cause adverse reactions, although not everyone experiences them.
Allergic reaction (hypersensitivity) is an uncommon adverse reaction (may occur in up to 1 in 100 people), but it may lead to a severe anaphylactic reaction, which can be fatal. If a patient notices symptoms of an allergic reaction after using the medicine, they should contact a doctor immediately.
The risk of bleeding is common. The risk depends on the dose, and most bleeding events are mild to moderate in severity. However, since the medicine was introduced to the market, cases of very severe, sometimes fatal, bleeding (haemorrhages) have been observed. Haemorrhages may occur at any site, including intracranial or retroperitoneal (abdominal) locations. The frequency of occurrence is unknown. In the event of significant bleeding, immediate medical advice must be sought.
Adverse reactions are listed below according to their frequency of occurrence.
Common (may affect up to 1 in 10 people):

• decreased platelet count (cells responsible for blood clotting) [mild, reversible thrombocytopenia (type I)]
• increased potassium levels in the blood (hyperkalaemia)
• haemorrhage (bleeding)
• transient increase in aminotransferase activity (liver enzymes: AspAT, AlAT)
• subcutaneous haematoma at the injection site
• pain at the injection site

Uncommon (may affect up to 1 in 100 people):

• hypersensitivity

Rare (may affect up to 1 in 1000 people):

• skin necrosis
• transient alopecia

Frequency not known (frequency cannot be estimated from available data):

• immune-mediated heparin-induced thrombocytopenia (type II, with or without associated thrombotic complications)
• anaphylactic reactions
• intracranial haemorrhage (some fatal)
• retroperitoneal haemorrhage (some fatal)
• rash
• subarachnoid or subdural haematoma

Heparin products may cause hypoaldosteronism (characterized by reduced aldosterone secretion— a hormone of the adrenal cortex), which may lead to increased serum potassium levels (hyperkalaemia). Clinically significant hyperkalaemia may occur particularly in patients with chronic renal failure and diabetes (see section 2: Warnings and precautions).
With long-term use of Fragmin, there is a risk of developing osteoporosis.
It is expected that adverse reactions in children will be the same as in adults; however, data on possible adverse reactions during long-term treatment in children are limited.
Reporting of adverse reactions
If any adverse reactions occur, including any possible adverse reactions not listed in this leaflet, inform your doctor or pharmacist. Adverse reactions can be reported directly to the Department of Monitoring Adverse Drug Reactions, Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Al. Jerozolimskie 181C
02-222 Warsaw
Phone: +48 22 49 21 301
Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
Adverse reactions can also be reported to the representative of the marketing authorization holder or to the marketing authorization holder directly.
Reporting adverse reactions helps to provide more information on the safety of the medicine.

5. How to store Fragmin

Keep the medicine out of the sight and reach of children.
Store pre-filled syringes and vials at a temperature below 25°C.
Fragmin 2 500 IU anti-Xa/ml, solution for injection: Do not store in the refrigerator or
freeze.
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the stated month.
From a microbiological point of view, the medicine should be used immediately. If it is not used immediately, the user is responsible for the storage conditions and duration of use.
Medicines must not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.

6. Contents of the pack and other information

What Fragmin contains

• The active substance in Fragmin is dalteparin sodium. The potency is expressed in international units (IU) anti-Xa according to the first International Standard for Low Molecular Weight Heparins.

• Other ingredients are:

What Fragmin looks like and contents of the pack
The injection solution is available in a pre-filled syringe with needle containing a single dose
of the medicinal product (Type I glass) with a needle cap (rubber), a plunger stopper (chlorobutyl rubber), a plunger
(polypropylene or polystyrene) with (or without) a Needle-Trap device as a safety feature. The needle cap
may contain latex.
The injection solution 2,500 IU anti-Xa/ml is available in a 4 ml vial made of colourless Type I glass,
with a siliconised Type I bromobutyl rubber stopper, an aluminium seal and a flip-off cap made of polypropylene, packed in a cardboard box.

Not all pack sizes may be marketed.
Marketing Authorisation Holder
Pfizer Europe MA EEIG
Boulevard de la Plaine 17
1050 Bruxelles
Belgium
Manufacturer
2,500 IU anti-Xa/0.2 ml; 5,000 IU anti-Xa/0.2 ml; 7,500 IU anti-Xa/0.3 ml
Pfizer Manufacturing Belgium NV
Rijksweg 12, 2870 Puurs-Sint-Amands
Belgium
Catalent France Limoges S.A.S.
Z.I. Nord, 53 rue de Dion Bouton
87280 Limoges
France
10,000 IU anti-Xa/0.4 ml, 2,500 IU anti-Xa/ml
Pfizer Manufacturing Belgium NV
Rijksweg 12, 2870 Puurs-Sint-Amands
Belgium
For more detailed information on this medicinal product, please contact the local representative of the Marketing Authorisation Holder:
Pfizer Polska Sp. z o.o.
tel. 22 335 61 00
Detailed and up-to-date information about this product can be obtained by scanning the QR code located on the outer packaging using a mobile device. The same information is also available at the following URL: https://pfi.sr/ulotka-fragmin and on the website of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products http://www.urpl.gov.pl.